A six-year risk assessment for dementia and Alzheimer's disease in the general population through immunoprecipitation-mass spectrometry plasma amyloid quantification
This research advances the potential application of plasma amyloid biomarkers for assessing the risk of clinical dementia and AD in the general population within short period of time, positioning it as a valuable tool alongside existing plasma PT217 biomarkers or using ratio of both of them.
Authors
- Claudine Berr (ORCID: https://orcid.org/0000-0001-5254-7655)
- Audrey Gabelle (ORCID: https://orcid.org/0000-0002-7648-9194)
- Catherine Helmer (ORCID: https://orcid.org/0000-0002-5169-7421)
- Sylvain Lehmann (ORCID: https://orcid.org/0000-0001-6117-562X)
- Jana Kindermans (ORCID: https://orcid.org/0000-0001-6218-7753)
- Christophe Hirtz (ORCID: https://orcid.org/0000-0002-7313-0629)
- Germain U. Busto (ORCID: https://orcid.org/0000-0002-8787-563X)
- Karim Bennys (ORCID: https://orcid.org/0000-0003-1363-0143)
- Isabelle Carrière (ORCID: https://orcid.org/0000-0002-3617-0752)
- Laure‐Anne Gutierrez (ORCID: https://orcid.org/0000-0003-1852-9263)
Institutions
- Université de Bordeaux (FR)
- Inserm (FR)
- Université de Montpellier (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Institute for Regenerative Medicine & Biotherapy (FR)
- Bordeaux Population Health (FR)
- Institute for Neurosciences of Montpellier (FR)
- Services déconcentrés d'appui à la recherche Occitanie-Montpellier (FR)
Publication Details
- Journal
- The Journal of Prevention of Alzheimer s Disease
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1016/j.tjpad.2025.100186
- Citations
- 1
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Sanofi
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale
- Fondation pour la Recherche Médicale
- Fondation de France
- Mutuelle Générale de l'Education Nationale